Format and content for post-market drug benefit-risk assessment in Canada. : H164-255/2019E-PDF
"The objective of this guidance document is to assist Market Authorization Holders (MAHs) in developing a post-market benefit-risk assessment for a marketed drug when requested"--Objective, page 1.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.865274&sl=0
| Department/Agency | Canada. Health Canada. |
|---|---|
| Title | Format and content for post-market drug benefit-risk assessment in Canada. |
| Publication type | Monograph |
| Language | [English] |
| Format | Electronic |
| Electronic document | |
| Note(s) | Issued also in French under title: Format et contenu des évaluations des avantages et des risques après la mise en marché au Canada. "Guidance document." Issued also in HTML format. Includes references. |
| Publishing information | Ottawa : Health Canada, 2019. ©2019 |
| Description | 1 online resource (iii, 15 pages) |
| ISBN | 9780660287041 |
| Catalogue number |
|
| Departmental catalogue number | Pub.: 180752 |
| Subject terms | Drugs |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.- Date modified: